Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Photo of Chris Lavy

The Technical Advisory Group on Integrated Clinical Care (the TAG-IC2) is a 22-strong member group of experts which advises WHO in the areas of clinical primary, emergency, operative, and critical care. Prof. Lavy is one of five members of a team that will advise WHO in the area of operative (surgical) care.  

“Our team will be reviewing guidelines, publications and other sorts of who materials in the surgical field and looking at setting out new ones if necessary,” said Chris. “In particular I’ll be looking at orthopaedics and trauma care.” 

One of Chris’s orthopaedic research interests is clubfoot and he’s set up the international Global Clubfoot Initiative to share expertise in clubfoot management. “We’ve discovered a lot about clubfoot through our studies, teaching and by delivering treatment to patients and children born with the condition. But as yet there is no global policy on its treatment. One of the reasons I’m part of the technical advisory group, is to help bring together some of the great ideas that have been tested across national programmes and diseases to be branded as global guidelines and protocols by the WHO.” 

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.